Fig. 2. CaM inhibitors block NE-induced cPLA₂ translocation to the nuclear envelope. VSMCs were treated with CaM inhibitors calmidazolium (CLMD, 1 µM), E₆-berbamine (E₆-B, 10 µM), W-7 (10 µM) or their vehicle (VEH). (A) cPLA₂ translocation to the nuclear envelope in cells treated with 10 µM NE or its vehicle (V) and visualized by confocal microscopy (100x magnification). (B) Density of cPLA₂ fluorescence around the nuclear envelope (n=5). ^*Value significantly different from the corresponding value obtained with V of NE (P<0.05).

Return to article